Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Rhea-AI Summary
Biohaven (NYSE: BHVN) reported Q1 2026 results and program updates on May 4, 2026. Cash and equivalents totaled approximately $351.8M as of March 31, 2026. Q1 R&D expense was $103.8M and net loss was $130.5M ($0.88/share). Multiple pivotal trial initiations and topline readouts are expected in 2H 2026.
Key near-term milestones include pivotal starts for BHV-1400 (IgAN) and BHV-1300 (Graves') mid-year, and topline results for opakalim (epilepsy) and taldefgrobep alfa (obesity) in 2H 2026.
Positive
- Cash and marketable securities of $351.8M as of March 31, 2026
- R&D expense down to $103.8M in Q1 2026 from $187.6M prior year
- Pivotal trial initiations planned mid-2026 for BHV-1400 (IgAN) and BHV-1300 (Graves')
- Topline readouts expected in 2H 2026 for opakalim (epilepsy) and taldefgrobep alfa (obesity)
Negative
- Reported GAAP net loss of $130.5M in Q1 2026
- Non-GAAP adjusted net loss of $102.2M for Q1 2026
- Previous-year operating spend was materially higher, indicating continued burn despite reductions
Key Figures
Market Reality Check
Peers on Argus
BHVN was modestly higher pre‑news (+0.42%). Peers were mixed: ARDX +14.58%, JANX +0.63%, while PHVS -5.03% and SNDX -8.26%; VERA was slightly lower (-0.28%). Moves do not indicate a synchronized sector trend.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Q4/FY 2025 earnings | Positive | -9.7% | Full‑year results with strong degrader data, cash raise, and R&D restructuring. |
| Nov 10 | Q3 2025 earnings | Positive | -5.7% | Q3 results, cash update, and strategic reprioritization toward late‑stage programs. |
| Aug 11 | Q2 2025 earnings | Positive | -9.0% | Q2 results with strong cash, reduced R&D, and positive degrader/oncology data. |
| May 12 | Q1 2025 earnings | Positive | -5.1% | Q1 results, large Oberland financing, higher R&D, and multiple 2025–2026 milestones. |
| Mar 03 | Q4/FY 2024 earnings | Positive | -13.8% | Q4/FY 2024 results, strong cash, priority review for troriluzole, and pipeline updates. |
Earnings and business update releases have consistently been followed by negative price reactions despite highlighting cash positions and clinical progress.
Over the past five earnings-related updates, Biohaven has repeatedly paired substantial cash balances and advancing clinical programs with sizable GAAP and non‑GAAP net losses. Prior quarters emphasized degrader platforms (BHV‑1300, BHV‑1400), opakalim, and taldefgrobep, alongside cost-optimization initiatives and R&D reprioritization. Yet, 24‑hour price reactions to these earnings events were negative after each release, with moves between -5.11% and -13.77%. Today’s Q1 2026 report continues the theme of a broad late‑stage pipeline and significant R&D spend reductions.
Historical Comparison
In the last five earnings updates, BHVN’s average 24‑hour move was -8.65%, with all events trading lower despite highlighting cash strength and clinical progress.
Earnings events show a shift from broad R&D spend toward focused investment in opakalim, degrader platforms, and taldefgrobep, accompanied by cost optimization efforts.
Market Pulse Summary
This announcement combines Q1 2026 financials with a dense slate of clinical milestones, including pivotal starts for BHV‑1300 and BHV‑1400 and expected topline data for opakalim and taldefgrobep in 2H 2026. The company reported R&D expenses of $103.8M, G&A of $26.6M, and cash of $351.8M. Historically, earnings releases have coincided with share price weakness, so tracking future reactions to similar updates and delivery on pivotal timelines may be important.
Key Terms
myostatin-activin pathway inhibitor medical
Kv7 ion channel activator medical
TYK2/JAK1 inhibitor medical
antibody-drug conjugate medical
ADC medical
pivotal trials medical
AI-generated analysis. Not financial advice.
- Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026.
- Advancement of high-value, late-stage priority programs:
- Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.
- Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026.
- TRAP™ and MoDE™ Degraders Advancing to Pivotal Trials
- Pivotal trials in both IgA nephropathy (IgAN) with Gd-IgA1 TRAP degrader, BHV-1400, and Graves' disease with IgG MoDE degrader, BHV-1300, expected to initiate by mid-year.
- Sustained progress across development pipeline:
- Enrollment in Phase 2 early Parkinson's disease trial with brain-penetrant TYK2/JAK1 inhibitor, BHV-8000, continues to advance.
- Enrollment advances in advanced endometrial cancer expansion cohort with the next-generation TROP-2 directed ADC BHV-1510 in combination with Libtayo®.
- Dose escalation advances with BHV-1530, a first-in-class FGFR3-directed antibody-drug conjugate (ADC). No dose-limiting toxicities observed to date.
- A total of 5 abstracts, including 1 oral presentation and 4 posters, featured at the American Academy of Neurology ("AAN") Annual Meeting
- Highlight's Biohaven leadership, innovative science, and development programs evaluating novel therapies to treat neurological and immunological diseases, including Kv7 ion channel activation, extracellular protein degradation, and TYK2/JAK1 inhibition.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "We are planning for a transformative year ahead at Biohaven, with multiple potential value-driving milestones on the horizon. In the coming several weeks, we expect the initiation of our pivotal clinical trials to advance our novel MoDE and TRAP extracellular protein degradation platform into two pivotal studies, BHV-1300 for Graves' disease and BHV-1400 for IgA nephropathy. These pivotal trials represent a key milestone for the degrader platform and further extends the clinical validation of our strategy to selectively degrade disease-causing proteins with our precision immunology technology. In the second half of 2026, we expect to report pivotal data from our epilepsy program and topline results from our obesity program."
Dr. Coric continued, "Additionally, our first-in-class FGFR3-directed ADC, BHV-1530, continues dose escalation with no dose-limiting toxicities observed to date, and we have begun an expansion cohort in advanced endometrial cancer with our next-generation TROP-2 directed ADC BHV-1510 in combination with Libtayo. We are also excited about progress with our TYK2/JAK1 inhibitor for early Parkinson's disease and continue to advance enrollment in this trial. Finally, our thought leadership in neurology was on display last month at AAN, where we notably delivered a total of 5 oral presentations and posters highlighting our differentiated neuroscience and immunoscience portfolio. Though our approach has been marked by a disciplined and careful management of resources, we are pleased with progress achieved in recent months and look forward to sharing more detailed and robust updates across our portfolio at our annual R&D Day at the Yale Innovation Summit on May 27, 2026 in
First Quarter and Recent Business Updates
First Quarter 2026 and Recent Business Highlights
- Completed Enrollment in Phase 2 Obesity Study with Taldefgrobep Alfa – Taldefgrobep alfa, a myostatin-activin pathway inhibitor, offers the potential to achieve high-quality weight loss in people living with obesity. Biohaven initiated a taldefgrobep Phase 2 proof-of-concept study in obesity in 4Q 2025. This randomized, placebo-controlled dose-ranging study is evaluating the efficacy and tolerability of once-weekly and once-monthly taldefgrobep as monotherapy, via self-administered autoinjector, in adults living with overweight and obesity. Topline data from the study are expected in 2H 2026.
- Oral and poster presentations at AAN underpinned breadth of development work across core programs - In April 2026, the Company delivered 1 oral presentation and 4 posters at the AAN Annual Meeting, showcasing development programs including Kv7 ion channel activation, extracellular protein degraders, and TYK2/JAK1 inhibition.
Expected Upcoming Milestones:
We believe Biohaven is well positioned to achieve significant, value-creating milestones in 2026 across numerous programs:
Selective Kv7 Ion Channel Activator (Opakalim):
- Continue two Phase 2/3 studies in focal epilepsy; initial topline results for the first study expected in 2H 2026.
Myostatin-Activin Pathway Inhibitor (Taldefgrobep alfa):
- Completed enrollment in Phase 2 study in obesity in 1Q 2026; topline results expected in 2H 2026.
Lead TRAP and MoDE Extracellular Protein Degraders (BHV-1400 and BHV-1300)
- BHV-1400: Pivotal study initiation in IgAN study expected mid-year 2026
- BHV-1300: Pivotal study initiation in Graves' disease expected mid-year 2026.
Capital Position:
Cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026, totaled approximately
First Quarter 2025 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were
General and Administrative (G&A) Expenses: G&A expenses, including non-cash share-based compensation costs, were
Other (Expense) Income, Net: Other (expense) income, net was other expense, net of
Net Loss: Biohaven reported a net loss for the three months ended March 31, 2026 of
Non-GAAP Financial Measures
This news release includes financial results prepared in accordance with accounting principles generally accepted in
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. The Company is advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms. Biohaven's extensive clinical and preclinical programs include Kv7 ion channel modulation for epilepsy; MoDE™ and TRAP™ extracellular protein degradation for immunological diseases; and myostatin inhibition for neuromuscular and metabolic diseases, including obesity.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected timing and amounts of funding under the NPA. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates and regarding reduction in annual direct R&D spend, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable
BIOHAVEN LTD. | ||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||
(Amounts in thousands, except share and per share amounts) | ||||
(Unaudited) | ||||
Three Months Ended March 31, | ||||
2026 | 2025 | |||
Operating expenses: | ||||
Research and development | $ 103,827 | $ 187,584 | ||
General and administrative | 26,601 | 33,977 | ||
Total operating expenses | 130,428 | 221,561 | ||
Loss from operations | (130,428) | (221,561) | ||
Other income, net | 168 | 493 | ||
Loss before provision for income taxes | (130,260) | (221,068) | ||
Provision for income taxes | 272 | 609 | ||
Net loss | $ (130,532) | $ (221,677) | ||
Net loss per share — basic and diluted | $ (0.88) | $ (2.17) | ||
Weighted average common shares outstanding— basic and diluted | 147,615,197 | 101,943,396 | ||
BIOHAVEN LTD. | ||||
CONSOLIDATED BALANCE SHEETS | ||||
(Amounts in thousands, except share amounts) | ||||
March 31, 2026 | December 31, 2025 | |||
(Unaudited) | ||||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 273,074 | $ 229,957 | ||
Marketable securities | 74,743 | 89,180 | ||
Prepaid expenses | 34,667 | 47,022 | ||
Other current assets | 3,165 | 2,170 | ||
Total current assets | 385,649 | 368,329 | ||
Property and equipment, net | 15,256 | 15,964 | ||
Intangible assets | 18,400 | 18,400 | ||
Goodwill | 1,390 | 1,390 | ||
Other non-current assets | 45,711 | 47,364 | ||
Total assets | $ 466,406 | $ 451,447 | ||
Liabilities and Shareholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 10,422 | $ 11,643 | ||
Accrued expenses and other current liabilities | 41,653 | 104,291 | ||
Total current liabilities | 52,075 | 115,934 | ||
Non-current operating lease liability | 38,363 | 39,958 | ||
Notes payable | 241,912 | 238,900 | ||
Other non-current liabilities | 4,556 | 4,583 | ||
Total liabilities | 336,906 | 399,375 | ||
Shareholders' Equity: | ||||
Preferred shares, no par value; 10,000,000 shares authorized, no shares issued | — | — | ||
Common shares, no par value; 200,000,000 shares authorized as of March 31, | 2,132,908 | 1,934,276 | ||
Additional paid-in capital | 203,358 | 193,984 | ||
Accumulated deficit | (2,215,068) | (2,084,536) | ||
Accumulated other comprehensive income | 8,302 | 8,348 | ||
Total shareholders' equity | 129,500 | 52,072 | ||
Total liabilities and shareholders' equity | $ 466,406 | $ 451,447 | ||
BIOHAVEN LTD. | ||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | ||||
(Amounts in thousands, except share and per share amounts) | ||||
(Unaudited) | ||||
Three Months Ended March 31, | ||||
2026 | 2025 | |||
Reconciliation of GAAP to Non-GAAP adjusted net loss: | ||||
GAAP net loss | $ (130,532) | $ (221,677) | ||
Add: non-cash share-based compensation expense | 28,286 | 53,062 | ||
Add: loss from change in fair value of derivatives | — | 1,790 | ||
Non-GAAP adjusted net loss | $ (102,246) | $ (166,825) | ||
Reconciliation of GAAP to Non-GAAP adjusted net loss per share — basic and diluted: | ||||
GAAP net loss per share — basic and diluted | $ (0.88) | $ (2.17) | ||
Add: non-cash share-based compensation expense | 0.19 | 0.51 | ||
Add: loss from change in fair value of derivatives | — | 0.02 | ||
Non-GAAP adjusted net loss per share — basic and diluted | $ (0.69) | $ (1.64) | ||
MoDE and TRAP are trademarks of Biohaven Therapeutics Ltd.
Libtayo is a registered trademark of Regeneron Pharmaceuticals, Inc.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Christy Curran
Sam Brown Inc.
christycurran@sambrown.com
615-414-8668
View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-reports-recent-business-developments-and-first-quarter-2026-financial-results-302761656.html
SOURCE Biohaven Ltd.